VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) announced participation in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. CEO David Domzalski will present at 12:30 p.m. ET and management will host investor meetings on the same day. A webcast link is provided for those interested in attending, with a replay available for 90 days post-event. VYNE is focused on developing innovative therapies for immuno-inflammatory conditions, utilizing its proprietary BET domain platform, including lead programs VYN201 and VYN202.

BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34^th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022.

Piper Sandler 34th Annual Healthcare Conference
Date:	Thursday, December 1, 2022
Time:	12:30 p.m. ET
Format:	Company presentation
1x1 Meetings:	Thursday, December 1, 2022
Webcast Link:	https://event.webcasts.com/starthere.jsp?ei=1582698&tp_key=84bac10d55
	a replay will be available on the VYNE website for 90 days, following the presentation

Please contact your Piper Sandler representative if you would like to schedule a one-on-one meeting during the conference.

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

 

FAQ

What is VYNE Therapeutics' participation in the Piper Sandler conference?

VYNE Therapeutics will present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 12:30 p.m. ET.

When will VYNE hold investor meetings?

Investor meetings will be held on December 1, 2022, in conjunction with the Piper Sandler conference.

What is the focus of VYNE Therapeutics?

VYNE Therapeutics focuses on developing innovative therapies for the treatment of immuno-inflammatory conditions.

What are the lead programs of VYNE Therapeutics?

VYNE’s lead programs include VYN201 (pan-BETi) and VYN202 (selective-BETi), utilizing their proprietary BET domain platform.

How can I access the VYNE Therapeutics presentation?

The presentation will be available via a webcast, and a replay can be accessed on VYNE's website for 90 days post-presentation.